- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Continue CT with 30 ongoing Indian subjects: CDSCO panel tells Novo-Nordisk on Insulin Icodec
New Delhi: Based on the safety data of 30 Indian subjects in the global clinical trial of Insulin Icodec, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to drug major Novo Nordisk for the continuation of the trial of the antidiabetic drug Insulin Icodec with already 30 ongoing Indian subjects.
This came after the drug major Novo Nordisk presented the safety data of 30 Indian subjects in compliance with clinical trial NOC (No Objection Certificate) condition no. 1. – "The firm should submit safety data of initial 30 subjects from India for review by CDSCO for further continuation of the trial."
Insulin icodec is a long-acting basal insulin analogue, intended for once-weekly treatment, being developed by Novo Nordisk, for the treatment of type 1 and type 2 diabetes mellitus. The product has a terminal half-life of approximately 196 hours. Clinical development is underway in several countries.
Insulin icodec works after subcutaneous injection and absorption into the circulation, Icodec monomers bind to albumin to form an essentially inactive depot, from which icodec molecules slowly reach insulin receptors at target tissues to stimulate glucose lowering. Insulin icodec once-weekly doses correspond to 0.29, 0.48, and 0.57 U/kg/day, anticipating equipotency to once-daily basal insulin.
At the recent SEC meeting for endocrinology and metabolism held on February 16 and 17, 2023, the expert panel reviewed the safety data presented by the drug major Novo Nordisk on 30 Indian subjects.
Furthermore, Novo Nordisk informed that global enrollment is over, therefore further no more subjects will be enrolled from India in the study.
Accordingly, after detailed deliberation, the committee recommended the continuation of the trial, which already has 30 ongoing Indian subjects.
Also Read:Sun Pharma Gets CDSCO panel nod to manufacture, market antidiabetic FDC drug
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.